Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59^® adjuvant

References

• Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005; 23:Suppl 1 S1 - 9; http://dx.doi.org/10.1016/j.vaccine.2005.04.018; PMID: 15908058
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23:Suppl 1 S10 - 25; http://dx.doi.org/10.1016/j.vaccine.2005.04.019; PMID: 15908062
   PubMed Web of Science ®Google Scholar
• Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54:530 - 8; http://dx.doi.org/10.1016/j.jinf.2006.09.017; PMID: 17097147
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179 - 86; http://dx.doi.org/10.1001/jama.289.2.179; PMID: 12517228
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159 - 69; http://dx.doi.org/10.1016/j.vaccine.2005.08.105; PMID: 16213065
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767 - 77; http://dx.doi.org/10.1017/S0022172400022610; PMID: 4509641
   PubMedGoogle Scholar
• McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418 - 25; http://dx.doi.org/10.1016/j.vaccine.2009.01.136; PMID: 19368783
   PubMed Web of Science ®Google Scholar
• Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37:427 - 39; http://dx.doi.org/10.1016/S0531-5565(01)00210-8; PMID: 11772530
   PubMed Web of Science ®Google Scholar
• Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69 - 75; PMID: 367490
   PubMed Web of Science ®Google Scholar
• Remarque EJ. Influenza vaccination in elderly people. Exp Gerontol 1999; 34:445 - 52; http://dx.doi.org/10.1016/S0531-5565(99)00007-8; PMID: 10433399
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Corsi MP, et al. The immune system in the elderly: I. Specific humoral immunity. Immunol Res 1999; 20:101 - 8; http://dx.doi.org/10.1007/BF02786466; PMID: 10580635
   PubMed Web of Science ®Google Scholar
• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25:3066 - 9; http://dx.doi.org/10.1016/j.vaccine.2007.01.025; PMID: 17275144
   PubMed Web of Science ®Google Scholar
• Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656 - 63; http://dx.doi.org/10.1016/j.vaccine.2007.08.042; PMID: 17913310
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172 - 80; http://dx.doi.org/10.1086/599790; PMID: 19508159
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121 - 7; http://dx.doi.org/10.1001/archinte.166.10.1121; PMID: 16717175
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177 - 84; http://dx.doi.org/10.1159/000069172; PMID: 12679609
   PubMed Web of Science ®Google Scholar
• Sindoni D, La Fauci V, Squeri R, Cannavo G, Bacilieri S, Panatto D, et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J Prev Med Hyg 2009; 50:121 - 6; PMID: 20099444
   PubMedGoogle Scholar
• de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007; 26:119 - 27; http://dx.doi.org/10.1016/j.vaccine.2007.10.051; PMID: 18063446
   PubMed Web of Science ®Google Scholar
• Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin Emerg Drugs 2008; 13:21 - 40; http://dx.doi.org/10.1517/14728214.13.1.21; PMID: 18321146
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650 - 8; http://dx.doi.org/10.1086/590434; PMID: 18652550
   PubMed Web of Science ®Google Scholar
• Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28:Suppl 4 D45 - 53; http://dx.doi.org/10.1016/j.vaccine.2010.08.028; PMID: 20713260
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308 - 18; http://dx.doi.org/10.1016/S0264-410X(00)00153-5; PMID: 10930686
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117:625 - 33; PMID: 1530193
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10:447 - 62; http://dx.doi.org/10.1586/erv.11.23; PMID: 21506643
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959 - 65; http://dx.doi.org/10.1016/j.vaccine.2009.08.101; PMID: 19751689
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Press Release (2009). FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm195483.htm.
   Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009; 4:e4384; http://dx.doi.org/10.1371/journal.pone.0004384; PMID: 19197383
   PubMed Web of Science ®Google Scholar
• Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.10.019; PMID: 19835829
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Cioppa GD, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011; 7; http://dx.doi.org/10.4161/hv.7.1.13411; PMID: 21285531
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563 - 71; http://dx.doi.org/10.1097/INF.0b013e31819d6394; PMID: 19561422
   PubMed Web of Science ®Google Scholar
• Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. Feb 25;28(9):2076-9.
   Google Scholar
• Kilbourne E. Inacitvated Influenza Vaccines. In: Plotkin A MEe, editor. Vaccines. Philadelphia: Saunders; 1994. 565–81.
   Google Scholar
• Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002; 191:203 - 8; http://dx.doi.org/10.1007/s00430-002-0147-9; PMID: 12458361
   PubMed Web of Science ®Google Scholar
• Li R, Fang H, Li Y, Liu Y, Pellegrini M, Podda A. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing 2008; 5:2; http://dx.doi.org/10.1186/1742-4933-5-2; PMID: 18289372
   PubMedGoogle Scholar
• Tsai T, Brestrich G, Nacci L, Knuf M, Wutzler P, Karvonen A, et al. Hemaglutinin inhibition and microneutralization antibodies in infants and children receiving seasonal trivalent influenza vaccine (TIV) or MF59-adjuvanted TIV (ATIV). Poster presented at the 29th annual European Society for Pediatric Infectious Disease (ESPID) meeting, 7-11 June 2011, The Hague, the Netherlands.
   Google Scholar
• Bocharov G, Quiel J, Luzyanina T, Alon H, Chiglintsev E, Chereshnev V, et al. Feedback regulation of proliferation vs. differentiation rates explains the dependence of CD4 T-cell expansion on precursor number. Proc Natl Acad Sci USA 2011; 108:3318 - 23; http://dx.doi.org/10.1073/pnas.1019706108; PMID: 21292990
   PubMed Web of Science ®Google Scholar
• Quiel J, Caucheteux S, Laurence A, Singh NJ, Bocharov G, Ben-Sasson SZ, et al. Antigen-stimulated CD4 T-cell expansion is inversely and log-linearly related to precursor number. Proc Natl Acad Sci USA 2011; 108:3312 - 7; http://dx.doi.org/10.1073/pnas.1018525108; PMID: 21292989
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, et al. Influenza vaccine immunology. Immunol Rev 2011; 239:167 - 77; http://dx.doi.org/10.1111/j.1600-065X.2010.00974.x; PMID: 21198671
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877 - 82; http://dx.doi.org/10.1073/pnas.0813390106; PMID: 19237568
   PubMed Web of Science ®Google Scholar
• Cusick MF, Wang S, Eckels DD. In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol 2009; 183:6432 - 41; http://dx.doi.org/10.4049/jimmunol.0901617; PMID: 19841175
   PubMed Web of Science ®Google Scholar
• Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008; 180:1758 - 68; PMID: 18209073
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937 - 43; PMID: 10074505
   PubMed Web of Science ®Google Scholar
• Center for Biological Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Silver Spring, MD: Food and Drug Administration, May 2007.
   Google Scholar
• Committee for proprietary medicinal products. Note for guidance on harmonisation of requirements for influenza vaccines. 12 March 1997, CPMP/BWP/214/96. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
   Google Scholar